Patients with type 2 diabetes have a greater chance of developing cardiovascular and renal disease a observation-based study

Authors

  • Shah Zeb Assistant Prof, Med B Unit, MMC Mardan
  • Muhammad Abbass Prof of Med-B Unit, MMC Hospital Mardan
  • Fazli Rabi Trainee Medical Officer Medical B MMC Hospital Mardan
  • Ali Zaman Trainee Medical Officer Medical B MMC Hospital Mardan
  • Muhammad Hussain Afridi Assistant Professor Diabetes and Endocrinology Unit Hayatabad Medical Complex Peshawar
  • Amjad Ali Prof of Medicine MMC Hospital Mardan

Keywords:

T2DM, CVD, CKD, Deaths

Abstract

Background: Despite years of study on risk methods, cardiovascular disease and kidney disease remain the top causes of death and morbidity in patients with Type-II diabetes. Methods: One hundred persons of both sexes participated in the study which took place from January to December of 2021 at the Mardan Medical Complex in Mardan, Pakistan. Participants' ages varied from 21 to 86 in this study A Observation-based research. All of the people there had type 2 diabetes. Participants provided a wealth of demographic information, including their ages, sexes, heights, weights, heart rates, blood sugar levels, amounts of saturated fat and sugar in their diets, whether or not they smoked, how often they exercised, what they ate, and if they suffered from any preexisting conditions. The rate of cardio-renal disease was calculated for everyone surveyed. Myocardial infarction, cardiac arrest, stroke, chronic kidney disease, all-cause mortality, and cardiovascular disease mortality were analysed.

Downloads

Download data is not yet available.

References

Castagno D, Baird‐Gunning J, Jhund PS, Biondi‐Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta‐analysis. Am Heart J. 2011; 162:938– 948.e2

Chiang JI, Jani BD, Mair FS, Nicholl BI, Furler J, O'Neal D, et al. Associations between multimorbidity, all-cause mortality and glycemia in people with type 2 diabetes: A systematic review. PLoS One. 2018;13(12):e0209585.

Chowdhury MZI, Yeasmin F, Rabi DM, Ronksley PE, Turin TC. Prognostic tools for cardiovascular disease in patients with type 2 diabetes: A systematic review and meta- analysis of C-statistics. J Diabetes Complicat. 2019;33(1):98–111.

Chowdhury MZI, Yeasmin F, Rabi DM, Ronksley PE, Turin TC. Prognostic tools for cardiovascular disease in patients with type 2 diabetes: A systematic review and meta- analysis of C-statistics. J Diabetes Complicat. 2019;33(1):98–111.

Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and microvascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32.

Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi‐ Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005; 366:1279–1289.

Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta- analysis. Lancet 2012;380:1662–73.

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail‐Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545–2559.

Gray BJ, Bracken RM. Turner D, Morgan K, Thomas M, Williams SP, Williams M, Rice S, Stephens JW; Prosiect Sir Gâr Group. Different type 2 diabetes risk assessments predict dissimilar numbers at 'high risk': a retrospective analysis of diabetes risk-assessment tools. Br J Gen Pract. 2015;65(641):e852–60

Horton R. Offline: COVID-19 is not a pandemic. Lancet. 2020;396(10255):874.

Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92. https://doi.org/10.101 6/S0140-6736(98)10279-9.

Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–8. https://doi.org/1 0.1161/CIRCULATIONAHA.105.548206.

Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002;13:1918–27. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(CVD)

Maqbool M, Cooper ME, Jandeleit-Dahm KAM. Cardiovascular disease and diabetic kidney disease. Semin Nephrol 2018;38:217–32.

McMahon GM, Hwang SJ, Fox CS. Residual lifetime risk of chronic kidney disease. Nephrol Dial Transplant. 2017;32:1705–9.

Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Ponikowski P; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31(6):703–11

Sosale A, Prasanna Kumar KM, Sadikot SM, et al. Chronic complications in newly diagnosed patients with Type 2 diabetes mellitus in India. Indian Journal of Endocrinology and Metabolism 2014; 18:355-360.

Wexler DJ.Sulfonylureas and cardiovascular safety: the final verdict?JAMA. 2019; 322:1147.

Zhang, R., Mamza, J.B., Morris, T. et al. Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med 20, 63 (2022).

Published

03-12-2022

How to Cite

Zeb, S., Abbass, M., Rabi, F., Zaman, A., Afridi, M. H., & Amjad Ali. (2022). Patients with type 2 diabetes have a greater chance of developing cardiovascular and renal disease a observation-based study. International Journal of Health Sciences, 6(S9), 4334–4340. Retrieved from https://sciencescholar.us/journal/index.php/ijhs/article/view/13726

Issue

Vol. 6 No. S9 (2022)

Section

Peer Review Articles
Copyright & Licensing

Copyright (c) 2022 International journal of health sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.

Most read articles by the same author(s)